WO2019164010A1 - Agent antitumoral contre le cancer de la vessie et méthode de traitement du cancer de la vessie - Google Patents

Agent antitumoral contre le cancer de la vessie et méthode de traitement du cancer de la vessie Download PDF

Info

Publication number
WO2019164010A1
WO2019164010A1 PCT/JP2019/007242 JP2019007242W WO2019164010A1 WO 2019164010 A1 WO2019164010 A1 WO 2019164010A1 JP 2019007242 W JP2019007242 W JP 2019007242W WO 2019164010 A1 WO2019164010 A1 WO 2019164010A1
Authority
WO
WIPO (PCT)
Prior art keywords
bladder cancer
antitumor agent
compound
salt
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2019/007242
Other languages
English (en)
Japanese (ja)
Inventor
フィリップ ジャンク
山田　孝之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of WO2019164010A1 publication Critical patent/WO2019164010A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the effect of treatment was determined according to the following criteria.
  • the evaluation object was confirmed by image diagnosis by MRI (nuclear magnetic resonance imaging), and judged according to the following criteria.
  • CR Complete Response
  • PR Partial Response
  • SD stable disease
  • PD progressive disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le problème abordé par la présente invention est de fournir un agent antitumoral contre le cancer de la vessie qui présente un effet contre le cancer de la vessie, et une méthode de traitement du cancer de la vessie. L'invention concerne un agent antitumoral contre le cancer de la vessie qui contient de la 1-(2-désoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine ou un sel ou un promédicament de celle-ci.
PCT/JP2019/007242 2018-02-26 2019-02-26 Agent antitumoral contre le cancer de la vessie et méthode de traitement du cancer de la vessie Ceased WO2019164010A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862635269P 2018-02-26 2018-02-26
US62/635,269 2018-02-26

Publications (1)

Publication Number Publication Date
WO2019164010A1 true WO2019164010A1 (fr) 2019-08-29

Family

ID=67688200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/007242 Ceased WO2019164010A1 (fr) 2018-02-26 2019-02-26 Agent antitumoral contre le cancer de la vessie et méthode de traitement du cancer de la vessie

Country Status (2)

Country Link
TW (1) TW202000207A (fr)
WO (1) WO2019164010A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023008511A1 (fr) 2021-07-29 2023-02-02 富士フイルム株式会社 Composition pharmaceutique et agent antitumoral pour des tumeurs présentant au moins une fonction bap1 ou pbrm1 altérée

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038001A1 (fr) * 1996-04-09 1997-10-16 Yamasa Corporation 1-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038001A1 (fr) * 1996-04-09 1997-10-16 Yamasa Corporation 1-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIURA, SHINJI ET AL.: "Antitumor activity of a novel orally effective nucleoside , 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine", CANCER LETTERS, vol. 129, 1998, pages 103 - 110, XP055213439, doi:10.1016/S0304-3835(98)00089-5 *
MIURA, SHINJI ET AL.: "Comparison of 1-(2-deoxy-2-fluoro-4-thio- beta -D-arabinofuranosyl)cytosine with gemcitabine in its antitumor activity", CANCER LETTERS, vol. 144, 1999, pages 177 - 182, XP055213437, doi:10.1016/S0304-3835(99)00221-9 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023008511A1 (fr) 2021-07-29 2023-02-02 富士フイルム株式会社 Composition pharmaceutique et agent antitumoral pour des tumeurs présentant au moins une fonction bap1 ou pbrm1 altérée
KR20240028451A (ko) 2021-07-29 2024-03-05 후지필름 가부시키가이샤 Bap1 및 pbrm1 중 적어도 하나의 기능 저하를 갖는 종양에 대한 의약 조성물 및 항종양제

Also Published As

Publication number Publication date
TW202000207A (zh) 2020-01-01

Similar Documents

Publication Publication Date Title
JP7523351B2 (ja) 肥満細胞症の治療のための併用療法
CN101589026B (zh) 治疗脑神经胶质瘤的方法
KR102377742B1 (ko) 암치료약
CN112807434B (zh) Perk抑制剂在制备肝癌药物的增效剂中的应用
JP2003523944A (ja) Ｐ−糖タンパク質修飾物質を用いる抗ウィルス療法
WO2021063332A1 (fr) Utilisation d'un inhibiteur d'ezh2 en association avec un inhibiteur de cdk4/6 dans la préparation d'un médicament pour le traitement d'une tumeur
TWI835050B (zh) 一種吡啶并[1,2-a]嘧啶酮類似物的應用
WO2015172712A1 (fr) Composition pharmaceutique pour injection avec effet synergique de la vitamine c et des médicaments antitumoraux
US11141421B2 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
EP3429582B1 (fr) Polythérapie pour traiter les maladies prolifératives
CN111346081A (zh) 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途
WO2019164010A1 (fr) Agent antitumoral contre le cancer de la vessie et méthode de traitement du cancer de la vessie
WO2019176984A1 (fr) Agent anti-tumoral, potentialisateur d'effet anti-tumoral et kit anti-tumoral
AU2017235350B2 (en) Combination therapy for proliferative diseases
CN111803489A (zh) 含笑内酯及其衍生物在垂体腺瘤治疗中的应用
US7863255B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
CN120813358A (zh) 用于治疗肿瘤的药物组合物
WO2019146129A1 (fr) Composition pharmaceutique contre une tumeur présentant une mutation de l'isocitrate déshydrogénase, agent antitumoral et utilisation associée
WO2019230595A1 (fr) Agent de traitement contre le cancer gastrique diffus
TW202539622A (zh) 包含n,n-二甲基亞雙胍的製劑、和包含n,n-二甲基亞雙胍與藥物的藥物組合、組合物、試劑盒及其用途和製備方法
US20240207301A1 (en) Pharmaceutical composition and anti-tumor agent for tumor having decreased function of at least one of bap1 or pbrm1
WO2025070603A1 (fr) Nouvelle polythérapie dirigée contre le cancer du sang
CN114948951A (zh) Fk506或其可药用衍生物和铁死亡诱导剂联合在制备治疗癌症的药物中的用途
JP2025501657A (ja) 膵臓がんを治療するための方法
TW202606659A (zh) Ｋｉｆ１８ａ抑制劑治療結直腸癌的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19757867

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19757867

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP